Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

Once C-diff is in the ascendancy it can be very hard ... only 6% of potential donors make it through the rigorous testing programme. Although this treatment is relatively new it has had staggering ...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce weight loss, but LPOXY Therapeutics has penned a $7.5 million biobucks deal ...